Cargando…

Effectiveness of Covid-19 vaccines (Covishield(TM) and Covaxin (®)) in healthcare workers in Mumbai, India: A retrospective cohort analysis

BACKGROUND: India started its vaccination programme for Coronavirus-19 infection (COVID-19) on 16 January 2021 with Covishield(TM) (Oxford/Astra Zeneca vaccine manufactured by Serum Institute of India) and Covaxin (®) (Bharat Biotech, India). We designed the present study to study the effectiveness...

Descripción completa

Detalles Bibliográficos
Autores principales:	Contractor, Aashish, Shivaprakash, Shashikala, Tiwari, Anjali, Setia, Maninder Singh, Gianchandani, Tarang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612509/ https://www.ncbi.nlm.nih.gov/pubmed/36301977 http://dx.doi.org/10.1371/journal.pone.0276759

Ejemplares similares

“Covishield and Covaxin” – India's contribution to global COVID-19 pandemic
por: Raina, Sunil Kumar, et al.
Publicado: (2021)

Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review
por: Das, Swarnali, et al.
Publicado: (2022)

Estimation of SARS-CoV-2 IgG Antibodies in Healthcare Worker-Administered Covishield and Covaxin Vaccines at a Tertiary Care Hospital in Jharkhand, India
por: Singh, Bishnupati, et al.
Publicado: (2023)

Comparison of in-hospital COVID-19 related outcomes between COVISHIELD and COVAXIN recipients
por: Suri, Tejas M., et al.
Publicado: (2022)

Polyfunctional CD4 T-cells correlating with neutralising antibody is a hallmark of COVISHIELD(TM) and COVAXIN(®) induced immunity in COVID-19 exposed Indians
por: Rakshit, Srabanti, et al.
Publicado: (2023)

Adverse effects after first and second dose of covishield and covaxin: A longitudinal study
por: Mittal, Amit, et al.
Publicado: (2022)

Prevalence, severity, and risk factor of breakthrough infection after vaccination with either the Covaxin or the Covishield among healthcare workers: A nationwide cross-sectional study
por: Krishna, Bhavya, et al.
Publicado: (2022)

Retrospective cohort analysis of survival of children living with HIV/AIDS in Mumbai, India
por: Acharya, Shrikala, et al.
Publicado: (2021)

2371. A study to describe the pattern of cutaneous adverse effects of COVID-19 vaccines (Covishield and Covaxin )
por: Mitra, Debdeep, et al.
Publicado: (2023)

Impact of prior vaccination with Covishield(TM) and Covaxin® on mortality among symptomatic COVID-19 patients during the second wave of the pandemic in South India during April and May 2021: a cohort study
por: Abhilash, Kundavaram Paul Prabhakar, et al.
Publicado: (2022)

Antibody response after first and second-dose of ChAdOx1-nCOV (Covishield(TM)®) and BBV-152 (Covaxin(TM)®) among health care workers in India: The final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study
por: Singh, Awadhesh Kumar, et al.
Publicado: (2021)

Covaxin: An overview of its immunogenicity and safety trials in India
por: Sharma, Rohit, et al.
Publicado: (2021)

Factors associated with survival in adult people living with HIV/AIDS (PLHAs) in Mumbai, India (2004-2019): A retrospective cohort study
por: Acharya, Shrikala, et al.
Publicado: (2021)

Barriers for Antiretroviral Therapy Adherence and Viral Suppression in Members of the Key Population in Mumbai, India: Implications for Interventions
por: Acharya, Shrikala, et al.
Publicado: (2021)

Myoglobinuria-induced Acute Kidney Injury Secondary to Covishield(TM) Vaccination
por: Fatima, Rana, et al.
Publicado: (2022)

Adverse events associated with Covishield vaccination among healthcare workers in a tertiary hospital in South India
por: T Sathyapalan, Dipu, et al.
Publicado: (2022)

Falsified COVISHIELD products in India and Uganda
Publicado: (2021)

Seroprevelance Survey of Healthcare Workers in a Covid Care Hospital in Mumbai, India
por: Rohra, Seema, et al.
Publicado: (2021)

Should we start looking at the elderly for human immunodeficiency virus infections? A study of trends of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus in Mumbai, Maharashtra, India
por: Malkani, Ram, et al.
Publicado: (2020)

Adverse events following immunisation (AEFI) of COVISHIELD vaccination among healthcare workers in Ghana
por: Marfoh, Kissinger, et al.
Publicado: (2023)

Anti SARS-CoV 2 IgG antibody response in fully vaccinated Covishield (AZD1222) and Covaxin (BBV-152) recipients: a study done in southern part of West Bengal, India
por: Satpathi, Partha Sarathi, et al.
Publicado: (2022)

Humoral antibody kinetics with ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Covaxin-Induced Lymphocytic Myocarditis
por: Mittal, Nitish, et al.
Publicado: (2022)

Online partner seeking and high-risk behaviour in men who have sex with men and male-to-female transgendered people in Mumbai, India: Implications for prevention strategies
por: Acharya, Shrikala, et al.
Publicado: (2023)

Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and B.1.617.2/Delta variant in India, 2021: a multi-centric hospital-based case-control study
por: Bhatnagar, Tarun, et al.
Publicado: (2022)

Prevalence of COVID-19 Antibodies in Healthcare Workers at the Peak of the Pandemic in Mumbai, India: A Preliminary Study
por: Singhal, Tanu, et al.
Publicado: (2020)

Herpes Zoster Following Covaxin Receipt
por: Muhie, Oumer Abdu, et al.
Publicado: (2021)

Dermatological Symptoms among Polyester Dyeing and Printing Workers in Mumbai
por: Paste, Vaishali, et al.
Publicado: (2023)

Clinical outcomes in individuals hospitalized with SARS-CoV-2 Delta variant (B.1.617.2) who had been vaccinated with Covishield (ChAdOx1) and Covaxin (BBV-152)
por: Munigela, Apoorva, et al.
Publicado: (2022)

WCN23-0557 Higher pro-inflammatory cytokines are associated with anti-SARS-CoV-2 spike protein-specific seroconversion after two doses of COVAXIN™, COVISHIELD™ vaccination in renal transplant recipients
por: Prasad, N., et al.
Publicado: (2023)

Prevalence of COVID-19 vaccines (Sputnik V, AZD-1222, and Covaxin) side effects among healthcare workers in Birjand city, Iran
por: Zare, Hamed, et al.
Publicado: (2021)

Side Effects after Second Dose of Covishield Vaccine among Healthcare Workers: A Descriptive Cross-sectional Study
por: Pokharel, Khilasa, et al.
Publicado: (2021)

Utility of the lateral flow urine lipoarabinomannan tuberculosis assay in patients with advanced HIV disease at antiretroviral therapy centres in Mumbai, India
por: Acharya, Shrikala, et al.
Publicado: (2022)

Assessment of occupational hazards among dentists practicing in Mumbai
por: Ramaswami, E, et al.
Publicado: (2020)

A multicentre retrospective study on quality and outcomes of cardiac rehabilitation programs in India
por: Chockalingam, Priya, et al.
Publicado: (2020)

The right to water in the slums of Mumbai, India
por: Subbaraman, Ramnath, et al.
Publicado: (2015)

Immunogenicity and safety of homologous and heterologous booster vaccination of ChAdOx1 nCoV-19 (COVISHIELD™) and BBV152 (COVAXIN®): a non-inferiority phase 4, participant and observer-blinded, randomised study
por: Rose, Winsley, et al.
Publicado: (2023)

Identification of awkward postures that cause discomfort to Liquid Petroleum Gas workers in Mumbai, India
por: Chowdhury, Salian Shivani, et al.
Publicado: (2012)

Effectiveness of COVID-19 vaccine (Covaxin) against breakthrough SARS-CoV-2 infection in India
por: Behera, Priyamadhaba, et al.
Publicado: (2022)

Side effects of Sputnik V, Oxford–AstraZeneca, Sinopharm, and Covaxin and their associations with other variables among healthcare workers of a tertiary hospital in Iran
por: Oghazian, Sahar, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fvk0d53k4r36frb7hgg6jhtfqh